Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Francesca Ruzzi

6PUBLICATIONS

18CO-AUTHORS

Cancer geneticsMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Solid tumours

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Feb 26, 2025

Chondrosarcoma: New Molecular Insights, Challenges in Near-Patient Preclinical Modeling, and Therapeutic Approaches.

Lorena Landuzzi, Francesca Ruzzi, Pier-Luigi Lollini

|Jan 30, 2025

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma.

Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino

|Dec 05, 2024

Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring <i>BRAF</i> Class 3 Mutations.

Alessandro Di Federico, Stefania Angelicola, Mariateresa Frascino

|Feb 09, 2024

IL-1 Family Members in Bone Sarcomas.

Lorena Landuzzi, Francesca Ruzzi, Evelin Pellegrini

|Aug 26, 2023

Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy.

Francesca Ruzzi, Maria Sofia Semprini, Laura Scalambra

|Feb 11, 2023

Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research.

Lorena Landuzzi, Francesca Ruzzi, Pier-Luigi Lollini

Pageof 1

Frequent Collaborators

5 joint publications

Pier-Luigi Lollini

3 joint publications

Lorena Landuzzi

3 joint publications

Katia Scotlandi

1 joint publications

Patrizia Nanni

1 joint publications

Evelin Pellegrini

1 joint publications

Maria Cristina Manara

1 joint publications

Alessandro Di Federico

1 joint publications

Stefania Angelicola

1 joint publications

Maria Sofia Semprini

1 joint publications

Hugo De Jonge

Frequent Collaborators

5 joint publications

Pier-Luigi Lollini

3 joint publications

Lorena Landuzzi

3 joint publications

Katia Scotlandi

1 joint publications

Patrizia Nanni

Top Related Videos

Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues

Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues

Published on : Mar 22, 2024

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on : Jul 07, 2023

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos

Top Related Videos

Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues

Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues

Published on : Mar 22, 2024

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on : Jul 07, 2023

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos